Lytix Biopharma (Q4 Review): Well-Funded to Deliver in 26′ - Redeye
Bildkälla: Stockfoto

Lytix Biopharma (Q4 Review): Well-Funded to Deliver in 26′ - Redeye

Redeye comments on Lytix' third quarter report 2025. After the quarter, NOK77m was raised in a directed and rights issue. This provides the company with a prolonged runway into 2027 after the NeoLipa readout in H2 2026. Verrica raised USD50m, providing it a runway into mid-2027.

Redeye comments on Lytix' third quarter report 2025. After the quarter, NOK77m was raised in a directed and rights issue. This provides the company with a prolonged runway into 2027 after the NeoLipa readout in H2 2026. Verrica raised USD50m, providing it a runway into mid-2027.
Börsvärldens nyhetsbrev